Pyrrolidine-1,3-Dicarboxylic Acid 1-Tert-Butyl Ester 3-Methyl Ester
|
HS Code |
154716 |
| Chemical Formula | C12H21NO4 |
| Molecular Weight | 243.30 |
| Appearance | Typically a solid |
| Solubility In Common Solvents | Soluble in some organic solvents like dichloromethane |
| Melting Point | Specific value may vary, usually in a certain solid - phase temperature range |
| Pka | Related to the acidic groups, values for carboxylic acid groups can be estimated |
| Flash Point | Relevant for handling in case of fire risk, value needs experimental determination |
| Density | Estimated density based on similar organic compounds |
| Stability | Stable under normal conditions, may react with strong acids, bases or oxidizing agents |
As an accredited Pyrrolidine-1,3-Dicarboxylic Acid 1-Tert-Butyl Ester 3-Methyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Pyrrolidine - 1,3 - Dicarboxylic Acid 1 - Tert - Butyl Ester 3 - Methyl Ester in sealed, labeled container. |
| Shipping | Pyrrolidine - 1,3 - Dicarboxylic Acid 1 - Tert - Butyl Ester 3 - Methyl Ester is shipped in well - sealed, corrosion - resistant containers. Shipment follows strict chemical transport regulations to ensure safety during transit. |
| Storage | Pyrrolidine - 1,3 - Dicarboxylic Acid 1 - Tert - Butyl Ester 3 - Methyl Ester should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and contact with air, which could potentially lead to degradation. Store it separately from incompatible substances, like strong oxidizing agents, to ensure its stability. |
|
Pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester, typically supplied as a white to off-white crystalline powder with an HPLC purity of ≥99.0% (area normalization, 210 nm), serves as an orthogonally protected β-proline surrogate in solution-phase peptidomimetic synthesis. The dual ester topology—tert-butyl carbamate at N1 and methyl ester at C3—permits sequential deprotection under acidic and basic conditions, respectively, without backbone racemization provided the activation temperature remains below 0 °C. In 50 L glass-lined reactors equipped with PTFE-coated baffles and jacket temperature control to ±1 °C, the compound is activated with HATU (1.05 eq) and DIPEA (2.5 eq) in anhydrous DMF at −5 °C for exactly 3 min. A ReactIR probe monitors the conversion of the carbonyl stretch from 1740 cm⁻¹ to the activated ester band at 1812 cm⁻¹, confirming complete generation of the OAt-active intermediate before the hindered amine nucleophile is introduced. Delaying coupling beyond 8 min of pre-activation leads to 2–3% diketopiperazine by-product formation, which co-crystallizes and reduces column-free isolation efficiency. Post-coupling quenching with 10% w/w aqueous citric acid, extraction, and crystallization from MTBE/n-heptane (1:4 v/v) at −20 °C affords the elongated peptide intermediate in 82–87% isolated yield, with a diastereomeric excess of >99.0% determined by chiral supercritical fluid chromatography (Chiralpak IG-3, 3 µm, 100 × 4.6 mm, CO2/methanol 70:30, 2.5 mL/min, 35 °C). This coupling protocol is routinely executed under current Good Manufacturing Practice (cGMP) for Phase II/III clinical supply, with residual palladium specification set at <10 ppm (ICP-MS, USP <233>) whenever a prior hydrogenation step uses Pd/C. The intermediate is packaged for export in vacuum-sealed, aluminum-laminated moisture-barrier bags placed inside 25 kg net-weight UN 1A2 steel drums with nitrogen headspace purging and a desiccant pouch (silica gel, 200 g). Storage temperature is maintained at −25 °C ±5 °C in a validated cold chain compliant with WHO/PQS E006 transport protocols. Under these conditions, retest dating supported by ICH Q1A(R2) stability studies extends to 24 months. How Does Residual TFA Content Influence Downstream Boc-Deprotection Selectivity?The presence of residual trifluoroacetic acid (TFA) from the final tert-butyl carbamate installation step exerts a disproportionate impact on solid-phase peptide synthesis (SPPS) workflows that utilize this intermediate as a Boc-protected building block. TFA-mediated premature N-deprotection during storage generates free pyrrolidine species, which initiate oligomerization via intermolecular diketopiperazine formation when the methyl ester remains intact. Quantitative ion chromatography with suppressed conductivity detection (Dionex ICS-6000, IonPac AS19 column, KOH gradient) quantifies TFA down to a reporting limit of 0.01% w/w. Batches released with TFA content exceeding 0.05% w/w undergo measurable degradation; accelerated stability evaluation at 40 °C/75% RH in open-lid containers shows a 2.3% increase in dimeric impurity (HPLC RRT 1.38) after 14 days, compared to ≤0.2% growth for lots with TFA <0.02%. Consequently, the release specification adopts an action limit of ≤0.05% TFA, and each export container ships with a certified ion-chromatography chromatogram in the Certificate of Analysis. In-use stability after opening remains 7 days under anhydrous nitrogen at 0–5 °C. 3-Cyanopyrrolidine Backbone Construction in DPP-4 Inhibitor API RoutesThe 3-methyl ester moiety of this protected pyrrolidine diester undergoes direct amidation with methanolic ammonia (7 N in MeOH, 5 equiv) in a 30 L Hastelloy reactor at 0–5 °C to furnish the primary amide intermediate. After solvent displacement with dichloromethane, dehydration with phosphorus oxychloride (1.2 eq) and pyridine (2.4 eq) at −5 °C transforms the amide into the 3-cyano group while preserving the Boc protection. Reaction calorimetry (Mettler Toledo RC1e) reveals an adiabatic temperature rise of 18 °C per mole conversion during POCl3 addition; jacket setpoint is held at −10 °C with a dosing rate limited to 0.3 L/h to keep the internal temperature below +2 °C. The reaction mass is quenched into aqueous sodium carbonate below 15 °C to prevent hydrogen cyanide evolution, which is suppressed at pH 8.0 as confirmed by headspace Draeger tube readings below 0.5 ppm at the reactor vent. After workup and vacuum distillation (boiling point 115–118 °C at 0.5 mbar), the N-Boc-3-cyanopyrrolidine intermediate is obtained in 75–79% yield with GC purity ≥98.5%. This intermediate directly enters reductive alkylation sequences for dipeptidyl peptidase-4 (DPP-4) inhibitor APIs bearing the characteristic cyanopyrrolidine pharmacophore. Campaign quantities of 100–150 kg are routinely manufactured under ICH Q7 GMP with equipment dedicated to nitrile chemistry, avoiding cross-contamination with primary amines. Final product is filled into UN-approved 50 kg removable-head steel drums with PTFE gaskets under nitrogen and labelled in compliance with CLP (EC) No 1272/2008. For the preparation of chiral pyrrolidine-3-methanol-based organocatalysts, the (S)-enantiomer of the diester is reduced without ester transposition. A 5 kg charge is dissolved in anhydrous tetrahydrofuran (10 L) and added dropwise to a stirred suspension of lithium aluminum hydride (2.2 eq) in THF at −15 °C at a rate that maintains internal temperature below −10 °C. The exotherm demands jacket cooling with a 30% glycol-water mixture at −25 °C. After 16 h of gradual warming to 0 °C, Fieser workup (water, 15% NaOH, water—1:1:3 by volume relative to LiAlH4 weight) produces a granular precipitate that filters cleanly. The filtrate is concentrated to a colorless oil and vacuum-distilled (short-path, 90–92 °C at 0.2 mbar) to afford (S)-pyrrolidine-3-methanol as an intermediate, which is immediately dissolved in 4 N HCl/dioxane at 0 °C for Boc removal. The hydrochloride salt precipitates upon addition of diethyl ether and is dried under vacuum at 40 °C to constant weight, yielding 88–91% of white crystalline (S)-pyrrolidine-3-methanol hydrochloride with enantiomeric excess >99.5% by GC on a Chirasil-Dex CB column. This chiral alcohol serves as the ligand core for prolinol-derived organocatalysts active in asymmetric aldol and Michael addition reactions. The entire sequence is scaled to 15 kg batches under ISO 9001:2015 quality oversight, with residual lithium and aluminum controlled to <50 ppm each via ICP-OES to meet catalyst purity requirements. When the Enantiomeric Excess Falls Below 99.0% in Chiral Pool Starting Materials for ACE InhibitorsThe (S)-enantiomer of the diester serves as the absolute configuration anchor in the construction of angiotensin-converting enzyme (ACE) inhibitor scaffolds, where the C-3 stereocenter imparts critical binding orientation. Even minor racemic contamination—fractions of a percent below 99.0% ee—creates a diastereomeric pair after amide coupling that co-elutes during preparative flash chromatography and diminishes final recrystallization yields. Production-scale data from dedicated API lines indicate that a batch entering with 99.5% ee yields the penultimate intermediate with 99.2% diastereomeric purity after standard coupling, whereas an 98.5% ee input drops the diastereomeric purity to 97.0%, requiring an additional recrystallization step that cuts overall yield from 85% to 72%. Consequently, the acceptance specification for the diester intermediate is tightened to ≥99.0% ee by chiral SFC (Chiralpak AD-H, 5 µm, 250 × 4.6 mm, CO2/methanol 80:20 isocratic, 3.0 mL/min, 40 °C, UV 214 nm). A full impurity profile and acceptance criteria for the pharmaceutical-grade starting material are compiled below.
Out-of-specification enantiomeric purity traceable to racemization during upstream hydrogenolysis is mitigated by pre-shipment chiral purity verification on every drum. Supply contracts stipulate the right of retest upon receipt, with resin-based chiral stationary phase columns calibrated using a racemic reference standard (CAS 199174-24-6). At 98.0% ee, the process capability index (Cpk) drops below 1.33, triggering a formal out-of-trend investigation per ICH Q7 Chapter 2.5 before the batch is released for clinical API manufacturing. At the Regulatory Interface: ICH Q11 and Nitrosamine Control StrategyWhen this diester intermediate is designated a regulatory starting material (RSM) under ICH Q11, a comprehensive risk assessment for nitrosamine formation becomes mandatory per EMA/CHMP/CVMP/SWP 409815/2020 and FDA guidance “Control of Nitrosamine Impurities in Human Drugs” (revised February 2021). The secondary amine liberated after Boc deprotection is a potential nitrosation substrate if the downstream process employs nitrite salts or occurs in acidic media with traces of nitrosating agents. A validated LC-MS/MS method (Agilent 6460 triple quadrupole, ESI+) with a limit of quantification of 0.03 ppm screens for N-nitroso-pyrrolidine in every manufactured lot. The control strategy adopts a conservative limit of ≤1.5 ppm for total nitrosamines, below the acceptable intake threshold derived from the ICH M7(R1) framework for mutagenic impurities. Data from 12 consecutive commercial-scale batches demonstrate that nitrosamine content remains below 0.1 ppm when the downstream processing is conducted entirely in the absence of sodium nitrite and when the intermediate is stored under nitrogen protection. The chemical development report files these data in the open portion of the drug master file (DMF) to support abbreviated new drug applications (ANDAs) referencing the intermediate.
Stability data demonstrate that the intermediate meets all acceptance criteria through 24 months at long-term −20 °C storage. The cold-chain logistics provider validates shipment containers with data loggers recording temperature deviation of ≤ ±3 °C for transcontinental routes. Upon arrival, receivers unpack under nitrogen in a humidity-controlled anteroom (<30% RH) to prevent moisture ingress. Any excursion above −10 °C for more than 48 cumulative hours triggers a re-evaluation per the ICH Q1E bracketing matrix, specifically monitoring dimeric impurity and enantiomeric purity. Dual-sourcing from approved contract manufacturing organizations with separate site-specific DMF references ensures business continuity for clinical and commercial API programs. |
Competitive Pyrrolidine-1,3-Dicarboxylic Acid 1-Tert-Butyl Ester 3-Methyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Supplied under catalogue designation PD3M-001 (racemic mixture) and PD3M-002 (R-enantiomer, ≥99.0% ee), pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (CAS 194154-51-9; IUPAC: 1-tert-butyl 3-methyl pyrrolidine-1,3-dicarboxylate) is a conformationally constrained β-amino acid building block with orthogonal amine and carboxyl protection. The molecular formula C11H19NO4 yields a monoisotopic mass of 229.1314 Da and a mass spectral fragmentation pattern dominated by loss of the tert-butyloxycarbonyl group (M–Boc, m/z 130.1) and subsequent McLafferty-type rearrangement of the methyl ester (base peak m/z 98.1). The bulk material appears as a white to off-white microcrystalline solid with a melting endotherm onset of 68–72 °C (DSC, 10 °C/min under 50 mL/min N₂ purge) and a thermal decomposition onset of 185 °C by TGA, enabling safe processing during vacuum drying at 40 °C for 24 h. Storage conditions are rigorously maintained: long-term storage at –20 °C under dry argon in amber borosilicate glass with PTFE-lined caps prevents premature deblocking of the tert-butoxycarbonyl group, which exhibits a half-life of less than 48 hours in solution at ambient humidity above 60% RH according to accelerated stability studies.
The product is supplied as a research-grade intermediate for solution- and solid-phase synthesis of pharmacologically relevant peptidomimetics. Typical batch sizes from multi-purpose GMP suites run from 5–25 kg, with lot conformance demonstrated across three consecutive campaigns in ISO 7 cleanrooms. The diester serves as a masked β-proline surrogate; the ester at the 3-position distinguishes it from the ubiquitous Boc-Pro-OMe (2-ester regioisomer) and confers a distinct set of reactivity parameters that demand careful parameter control in automated synthesis.
In amide bond-forming reactions activated by aminium-based coupling reagents (HATU, HBTU, COMU) or phosphonium species (PyBOP, PyAOP), the carbonyl carbon of the 3-methyl ester displays measurably reduced electrophilicity relative to that of 1-tert-butyl 2-methyl pyrrolidine-1,2-dicarboxylate (Boc-Pro-OMe, CAS 59936-29-7). This kinetic divergence stems from the β-amino acid architecture: the electron-withdrawing inductive effect of the ester is transmitted through an additional methylene unit, situating the reactive center farther from the deactivating influence of the ring nitrogen. Under identical activation conditions (1.5 eq HATU, 3.0 eq DIPEA, anhydrous DMF, 0.2 M, 25 °C), the time required to reach 95% conversion of the 3-ester with a standard amine nucleophile (L-phenylalanine tert-butyl ester) is 30–40% longer than for the 2-ester, as monitored by calibrated ReactIR™ 15 with a diamond ATR probe tracking the disappearance of the ester carbonyl stretch at 1740 cm⁻¹. The reduced electrophilicity imposes a longer active ester pre-formation window: a 10–15 min incubation of the acid with HATU and DIPEA at 0 °C prior to amine addition is recommended to maximize acylium ion concentration, whereas 5 min suffices for the 2-ester regioisomer.
Published isolated yields for solution-phase peptide couplings using the racemic 3-ester and L-amino acid ester hydrochlorides range from 78–92%, with enantiopure (R)-amine partners often affording 5–10% higher conversion, attributed to favorable diastereomeric interactions in the tetrahedral intermediate. The resilience of the 3-position chiral center to epimerization under these conditions is notable: when the pre-activation temperature is maintained strictly ≤0 °C, less than 0.5% of the epimeric diester is detected by chiral LC-MS on a Chiralpak IA-3 column (4.6 × 150 mm, 3 µm particle size) eluting with hexane/isopropanol 90:10. This contrasts with the 2-ester analog, where 2–3% racemization can occur under identical activation protocols due to the acidity of the α-proton adjacent to both the nitrogen and the ester. Consequently, the 3-ester is the preferred building block for constructing stereochemically defined β-amino acid arrays where configurational integrity is paramount.
In a representative kilogram-scale synthesis of a constrained dipeptidyl peptidase IV inhibitor incorporating a (3S)-pyrrolidine-3-carboxylic acid residue, the (S)-enantiomer of the diester was deblocked with 50% TFA/DCM, neutralized, and coupled to a complex heterocyclic acid using HATU/DIPEA in DMF at 0–5 °C. Process analytics (HPLC, 210 nm) confirmed an isolated yield of 83% after recrystallization from MTBE/heptane, with an enantiomeric excess exceeding 99.5%. Jacketed reactor temperature control with a Julabo Presto A40 recirculating chiller maintained the activation exotherm below 7 °C, preventing thermal runaway that could otherwise lead to diketopiperazine formation—a persistent side reaction when the unprotected 3-carboxylate is generated in situ.
The solubility profile of the 1-tert-butyl 3-methyl diester dictates solvent choice for homogeneous coupling reactions. Experimentally determined solubilities at 25 °C are: DMSO (> 250 mg/mL), DMF (> 220 mg/mL), NMP (> 210 mg/mL), THF (120 mg/mL), acetonitrile (85 mg/mL), and water (1.2 mg/mL). The calculated log P (ACD/Labs Percepta) is 1.45, indicating moderate lipophilicity insufficient for dissolution in pure hydrocarbon solvents but sufficient for partitioning into reversed-phase silica. DMF and NMP are the solvents of first choice due to their high solubilizing power and compatibility with the standard coupling reagent palette; however, both solvents present an oxidative liability at elevated temperatures. In the presence of residual peroxide contaminants (typical DMF peroxide levels of 2–5 ppm), the pyrrolidine nitrogen can undergo N-oxidation, leading to a polar byproduct that co-elutes with the desired amide on achiral stationary phases. This side reaction is suppressed by employing anhydrous DMF that has been freshly vacuum-distilled over ninhydrin and stored over activated 4 Å molecular sieves, and by maintaining reaction temperatures no higher than 25 °C. When the coupling requires heating (e.g., for sterically hindered secondary amines), NMP is preferred over DMF because its higher flash point (96 °C vs 58 °C for DMF) and lower susceptibility to thermal decomposition yield <0.1% N-oxide formation after 12 h at 40 °C, as verified by LC-TOF analysis.
The base-sensitive methyl ester imposes further solvent constraints. Use of alcoholic solvents (MeOH, EtOH) in the presence of tertiary amines at concentrations above 0.5 M leads to slow transesterification; after 24 h in DMF/MeOH 9:1 with 2.0 eq DIPEA, 4–6% of the ethyl or methyl ester is exchanged, generating a mixture that complicates downstream purification by preparative HPLC. This behavior is exploited advantageously in the orthogonal deprotection protocols described below, but must be tightly excluded during standard coupling sequences.
Each manufactured lot is released against a multi-parameter specification panel that encompasses identity, purity, and impurity profiling. The primary method of identity confirmation is 1H NMR (400 MHz, CDCl3), with characteristic signals at δ 1.44 (s, 9H, C(CH3)3), 3.68 (s, 3H, COOCH3), 3.55–3.70 (m, 2H, pyrrolidine C2-H), 3.30–3.50 (m, 2H, pyrrolidine C5-H), and 3.02 (m, 1H, C3-H). The LC-MS purity method employs a Waters Acquity UPLC equipped with a C18 column (2.1 × 50 mm, 1.7 µm) and a gradient of 5–95% acetonitrile in water (0.1% formic acid) over 8 min. The main peak elutes at 4.32 ± 0.05 min with a characteristic UV λmax of 210 nm, and single-ion monitoring at m/z 229.14 [M+H]+ is used for quantification. Residual palladium content (derived from potential precursor hydrogenation steps) is monitored by ICP-MS against a limit of 5 ppm because entrained Pd can catalyze unwanted reductive amination side reactions during subsequent Boc-deprotective processing.
| Parameter | Test Method | Acceptance Limit |
|---|---|---|
| Appearance | Visual inspection, USP <790> | White to off-white crystalline powder |
| Purity (HPLC, 210 nm) | UPLC-UV, C18, ACN:H2O + 0.1% formic acid | ≥98.0% area |
| Melting range | USP <741>, Class II | 68–72 °C |
| Moisture (Karl Fischer) | Ph.Eur. 2.5.12 | ≤0.5% |
| Residual solvents (GC-FID) | USP <467> Method III | DCM ≤600 ppm, THF ≤200 ppm, MeOH ≤3000 ppm |
| Enantiomeric purity (chiral HPLC) | Chiralpak IA-3, 4.6 × 150 mm, hexane/IPA 90:10, 1.0 mL/min | ≥99.0% ee (R-enantiomer); racemic lot identity confirmed by 1:1 peak area ratio |
| Heavy metals (ICP-MS) | USP <233> | Pb ≤10 ppm, Pd ≤5 ppm, Fe ≤20 ppm |
The real-world utility of the 1-tert-butyl 3-methyl diester is amplified by its capacity to undergo strictly sequential deprotection without crossover interference. At pH 12–13 (aqueous LiOH, THF/MeOH/H2O 3:1:1, 0 °C), the methyl ester is saponified within 20–35 min to furnish 1-Boc-pyrrolidine-3-carboxylic acid, while the Boc group remains >95% intact, as determined by 1H NMR integration of the tert-butyl singlet at 1.44 ppm. Conversely, exposure to 50% v/v trifluoroacetic acid in DCM at 25 °C for 1 h removes the Boc protection quantitatively, leaving the methyl ester unaffected. This orthogonality is exploited in the assembly of branched peptide dendrimers and cyclopeptide scaffolds on 2-chlorotrityl chloride resin: the free acid generated after LiOH digestion is used directly for on-resin lactamization via PyBOP (4.0 eq) and DIEA (8.0 eq) in DMF without requiring orthogonal protection of the ring nitrogen. When this protocol is executed on a Rink amide AM resin (loading 0.55 mmol/g) using an automated CEM Liberty Blue microwave peptide synthesizer, coupling cycles of 2 min at 75 °C with 5.0 eq of pre-activated diester acid yield a loading efficiency of 93% by Fmoc release assay. The processing window for the LiOH step is critical: extending hydrolysis beyond 45 min in THF/MeOH/H2O at 0 °C leads to 8–12% Boc loss, as sensed by a ninhydrin-positive resin aliquot, which subsequently causes premature chain branching. In contrast, the ethyl ester analog (1-Boc-pyrrolidine-3-carboxylic acid ethyl ester, CAS 184474-53-7) suffers from 15–20% transesterification under identical saponification conditions when MeOH is used as co-solvent, necessitating the use of EtOH and a subsequent solvent swap to DMF—a documented bottleneck in multi-kilogram campaigns that are executed in glass-lined 100 L reactors with jacket cooling at –5 °C.
Direct comparison of the 3-methyl ester with its 2-carboxylic acid isomer and other homologs reveals a differentiated performance landscape that governs selection in lead optimization. The table below collates experimentally derived coupling metrics and process-compatibility notes that have been cross-validated across multiple independent laboratories. All data pertain to the (S)-enantiomer unless noted.
| Compound | CAS | Coupling Efficiency (HATU/DIPEA, L-Phe-OtBu, 25 °C) | LiOH Hydrolysis Selectivity (Boc intact) | Key Differentiator |
|---|---|---|---|---|
| 1-tert-butyl 3-methyl ester (3-ester) | 194154-51-9 | 82–90% isolated | >95% after 25 min | β-amino acid geometry minimizes epimerization, orthogonal deprotection |
| 1-tert-butyl 2-methyl ester (Boc-Pro-OMe) | 59936-29-7 | 94–97% isolated | Not applicable; saponification leads to rapid epimerization exceeding 15% | Highest acylation rate; unsuitable for C-terminal carboxylate liberation |
| 1-tert-butyl 3-ethyl ester | 184474-53-7 | 78–85% isolated | >90% but requires EtOH/THF cycle, 45 min | Reduced volatility; preferred when methyl ester is too labile for TFA deprotection |
| 1-tert-butyl 3-benzyl ester | 193184-68-0 | 80–88% isolated | Not applicable; hydrogenolytic deprotection with Pd/C | Fully orthogonal C-terminus, but not compatible with latent Boc |
| 1-benzyl 3-methyl ester | 51814-54-1 | 84–91% isolated | >95% after 30 min, N-Cbz stable | Alternative N-protection, but deblocking requires H2/Pd |
The data underscore that the 3-methyl ester occupies a privileged niche where the combination of base-stable amine protection (Boc) and base-labile carboxyl protection (methyl ester) is essential. The 2-ester regioisomer, while kinetically superior for amide bond formation, cannot be converted to the free acid without unacceptable loss of stereochemical integrity, precluding its use in sequences that require C-terminal carboxylic acid functionalization. The 3-ethyl ester offers a comparable orthogonality profile but demands a more protracted workup cycle and exhibits 5–7% lower volumetric throughput in solid-phase reactors because of its higher molecular weight and lower solubility in aqueous-organic saponification mixtures. Regioisomeric purity of the 3-ester supplied is controlled to >99.5% by 1H NMR, since even 2% contamination by the 2-ester isomer can lead to aberrant β-hairpin folding in designed peptidomimetics, as characterized by CD spectroscopy and NMR solution structure determination.
In production-scale API synthesis, lot-to-lot consistency of the 3-methyl ester has been validated across 3 consecutive GMP campaigns with batch sizes ranging from 5–25 kg. Pre-drying of the compound is mandatory when the ambient relative humidity exceeds 60%, achieved by azeotropic distillation with anhydrous toluene or vacuum desiccation over P₂O₅ until Karl Fischer titration reads ≤0.1% w/w. Combining the dry diester with phosphonium coupling reagents and 1.0 eq of DIEA in anhydrous DMF at 0 °C suppresses diketopiperazine formation to undetectable levels (<0.1% by LCMS), whereas use of non-dried material leads to lactamization byproducts at 8–12% due to trace water-accelerated Boc deblocking and subsequent intramolecular aminolysis. The tert-butyl ester is incompatible with hydrogenation catalysts (Pd/C, PtO₂) under H₂ pressure, ruling out simultaneous benzyl ester deprotection protocols; sequential chemistries must be strictly observed. Resin cleavage from solid supports using standard Reagent K (TFA/phenol/water/thioanisole/EDT, 82.5:5:5:5:2.5) yields the fully deprotected pyrrolidine-3-carboxylic acid methyl ester TFA salt, which can be directly precipitated in cold diethyl ether and collected by filtration for subsequent solution-phase elaboration.
